<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414530</url>
  </required_header>
  <id_info>
    <org_study_id>2010-03-018</org_study_id>
    <nct_id>NCT01414530</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive During Menopausal Transition</brief_title>
  <official_title>Effects of Oral Contraceptive on Muscle or Joint Ache in Women During Menopausal Transition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle or joint pain is one of the most common symptoms during menopausal transition. As this&#xD;
      could be severe enough to affect social and daily life and to reduce quality of life,&#xD;
      attentions should be paid about this.&#xD;
&#xD;
      Although understanding of muscle or joint pain related to menopause is still insufficient,&#xD;
      estrogen can play an important role. Previous studies have shown that estrogen protects&#xD;
      cartilage in both animals and humans.&#xD;
&#xD;
      However, perimenopause is different from postmenopause, in the point that estrogen is still&#xD;
      secreted with a great fluctuation.&#xD;
&#xD;
      Until now, no study has been performed to evaluate the effects of oral contraceptive on&#xD;
      muscle or joint pain in women during menopausal transition. Moreover, since menopausal&#xD;
      symptoms vary according to ethnicity and culture, a study in Korean population is necessary.&#xD;
&#xD;
      Therefore, this randomized controlled trial was designed to evaluate the effects of oral&#xD;
      contraceptive on muscle or joint pain in women during menopausal transition, compared to&#xD;
      NSAID (non-steroidal anti-inflammatory drug).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in symptoms</measure>
    <time_frame>Eight weeks</time_frame>
    <description>evaluated by fibromyalgia impact questionnaire and visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>Eight weeks</time_frame>
    <description>evaluated by SF-12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Perimenopause</condition>
  <arm_group>
    <arm_group_label>oral contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive</intervention_name>
    <description>ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks</description>
    <arm_group_label>oral contraceptive</arm_group_label>
    <other_name>Minivora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NSAID</intervention_name>
    <description>ibuprofen 200mg/arginine 185mg twice per day for 8 weeks</description>
    <arm_group_label>NSAID</arm_group_label>
    <other_name>Carol-F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Perimenopausal women aged 45 or more&#xD;
&#xD;
          -  Women who have multiple joint or muscle pain for at least 3 months (at least two sites&#xD;
             out of upper and lower extremities or axial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis, ankylosing spondylitis, rheumatic polymyalgia, Inflammatory&#xD;
             myopathy&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  History of hysterectomy or bilateral oophorectomy&#xD;
&#xD;
          -  Vasomotor symptoms&#xD;
&#xD;
          -  History of surgery of musculoskeletal system&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Abnormalities of thyroid function&#xD;
&#xD;
          -  Focal neurologic deficit&#xD;
&#xD;
          -  Smoking within 1 year&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Coronary heart disease&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Stoke&#xD;
&#xD;
          -  Active thromboembolism&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
&#xD;
          -  Acute hepatic dysfunction&#xD;
&#xD;
          -  Gastrointestinal ulcer&#xD;
&#xD;
          -  Severe renal dysfunction&#xD;
&#xD;
          -  Hypersensitivity to drugs&#xD;
&#xD;
          -  Current hormone user or past users within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Byung-Koo Yoon, MD, PhD</last_name>
    <phone>82-2-3410-3512</phone>
    <email>bkyoon.yoon@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Koo Yoon</last_name>
      <phone>82-2-3410-3512</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Byung-Koo Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

